Melanoma Trial, Recruiting (NCT03809585)

Melanoma Trial, Recruiting NCT03809585 Sponsor: Oregon Health and Science University Condition: Melanoma

Printed from Voxsanity (voxsanity.com.au) — NCT03809585 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Melanoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

If you have an iris tumor:

You have been diagnosed with a tumor on the colored part of your eye (iris), which may be pigmented (dark) or non-pigmented (light-colored)

If you are joining as a healthy volunteer:

Your eyes have no known defects, damage, or growths on the colored part of your eye (iris)

Who may not be able to join:

You are unable to give your agreement to take part in the study after being informed about it
You have difficulty keeping your eye still enough for the eye scanning equipment used in this study
You are unable to attend all the required appointments for this study
You have other eye conditions affecting the back of the eye, increased eye pressure (glaucoma), or other conditions that may affect blood flow in the iris
You have very advanced cataracts that significantly reduce your vision (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: David Huang, MD, PhD, Oregon Health and Science University

Phone: 503-494-4351

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03809585

Sponsor: Oregon Health and Science University

Phase: Not Applicable

Status: Recruiting

Condition: Melanoma

Trial contact: 503-494-4351

More information: https://clinicaltrials.gov/study/NCT03809585

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

If you have an iris tumor:

You have been diagnosed with a tumor on the colored part of your eye (iris), which may be pigmented (dark) or non-pigmented (light-colored)

If you are joining as a healthy volunteer:

Your eyes have no known defects, damage, or growths on the colored part of your eye (iris)

Who may not be able to join:

You are unable to give your agreement to take part in the study after being informed about it
You have difficulty keeping your eye still enough for the eye scanning equipment used in this study
You are unable to attend all the required appointments for this study
You have other eye conditions affecting the back of the eye, increased eye pressure (glaucoma), or other conditions that may affect blood flow in the iris
You have very advanced cataracts that significantly reduce your vision (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Oregon Health and Science University

Registry

ClinicalTrials.gov

Start date

20 June 2018

Est. completion

1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Tumor Thickness in Benign vs Malignant Iris Lesions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov